Paper1980339
Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells.
Klein E and 2 others. Mol Immunol, 1990. Cited by 40 papers, by iCite.
Cite this record
ConductScience Library. Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Papers, record 1980339. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1980339
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Complement C3b | Major topic |
| Cytotoxicity, Immunologic | Major topic |
| Killer Cells, Natural | Major topic |
| Lymphocyte Function-Associated Antigen-1 | Major topic |
| Receptors, Complement | Major topic |
| Antigens, CD | |
| CD18 Antigens | |
| Humans | |
| Macrophage-1 Antigen | |
| Receptors, Complement 3b | |
| Receptors, Leukocyte-Adhesion |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 2RO1 CA25250-10 | NCI NIH HHS | United States | RO1CA252501 | PubMed | NIH RePORTER |
| R01CA025250 | NIH | NIH RePORTER |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40904461 | The complement system in human pregnancy and preeclampsia. | Front Immunol | 2025 | https://conductscience.org/library/papers/40904461 | PubMed |
| 35197461 | Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection. | Nat Commun | 2022 | https://conductscience.org/library/papers/35197461 | PubMed |
| 34886361 | β-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19). | Int J Environ Res Public Health | 2021 | https://conductscience.org/library/papers/34886361 | PubMed |
| 31144209 | Complement System: a Neglected Pathway in Immunotherapy. | Clin Rev Allergy Immunol | 2020 | https://conductscience.org/library/papers/31144209 | PubMed |
| 28710915 | Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805. | Transl Oncol | 2017 | https://conductscience.org/library/papers/28710915 | PubMed |
| 24906530 | Complement in monoclonal antibody therapy of cancer. | Immunol Res | 2014 | https://conductscience.org/library/papers/24906530 | PubMed |
| 23474221 | Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. | Mol Oncol | 2013 | https://conductscience.org/library/papers/23474221 | PubMed |
| 19515245 | The effects of beta-glucan on human immune and cancer cells. | J Hematol Oncol | 2009 | https://conductscience.org/library/papers/19515245 | PubMed |
| 16595791 | Interactions between natural killer cells, cortisol and prolactin in malaria during pregnancy. | Clin Med Res | 2006 | https://conductscience.org/library/papers/16595791 | PubMed |
| 9933447 | Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules. | Clin Exp Immunol | 1999 | https://conductscience.org/library/papers/9933447 | PubMed |
| 8690804 | Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. | J Clin Invest | 1996 | https://conductscience.org/library/papers/8690804 | PubMed |
| 8485905 | CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. | Clin Exp Immunol | 1993 | https://conductscience.org/library/papers/8485905 | PubMed |
| 8306367 | Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. | Cancer Immunol Immunother | 1994 | https://conductscience.org/library/papers/8306367 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| C3 | 718 | PubTator's text mining | https://conductscience.org/library/genes/718 | NCBI Gene |
| CRIPTO3 | 6998 | PubTator's text mining | https://conductscience.org/library/genes/6998 | NCBI Gene |
| FCGR3A | 2214 | PubTator's text mining | https://conductscience.org/library/genes/2214 | NCBI Gene |
| ITGAM | 3684 | PubTator's text mining | https://conductscience.org/library/genes/3684 | NCBI Gene |
| ITGB2 | 3689 | PubTator's text mining | https://conductscience.org/library/genes/3689 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1980339
GET https://conductscience.org/api/papers/v1/1980339/authors